Novavax Inc (NVAX)
$179.01
0.00 (0.00%)
NVAX Stock Quote Delayed 30 Minutes
Novavax Stock May Not Get the Delta Varient Bump Investors Need
While NVAX stock may enjoy increased relevance on paper due to the delta variant, investors should think about the bigger picture.
Louis Navellier's Top 6 Stocks for 2021
He found Apple at $1.49… Intel at $3.60... Amazon at $46. Now, investing legend Louis Navellier is revealing his Top 6 Stocks for 2021 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
13.26B
PE Ratio
-18.96
EPS
-9.44
Volume (Avg. Vol.)
6,697
Day's Range
179.01 - 179.01
52-Week Range
76.59 - 331.68
Dividend & Yield
N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
Plenty of Upside Potential Looms Ahead of Novavax Stock’s Bumpy Road
NVAX stock has had a turbulent 2021, but with its Covid-19 vaccine expected to go into product in Q4, growth looms.
NVAX Stock: One Big Reason Novavax Is Struggling Today
Today's significant selloff appears to be tied at least in part to some large stock sales made by the company's CEO earlier this month.
Novavax Stock Should Take Off as Its Successful Covid-19 Vaccine Spreads
Novavax should take off as its successful Covid-19 vaccine spreads. NVAX stock is worth at least 50% more, given a mixture of analysts’ estimates and comp analysis.
The Real Value of Novavax Lies in Its Pipeline, Not the Pandemic
NVAX stock is beginning to look like all the good news is priced in. However, a successful Covid-19 vaccine may be a catalyst for other vaccines.
NVAX Stock Is Not For The Faint Of Heart
On June 14, Novavax announced that its Covid-19 vaccine, officially called "NVX-CoV2373," proved to be 93% effective against the Coronavirus and its variants in a phase 3 clinical trial. The vaccine was 100% effective against severe versions of Covid-19. The Gaithersburg, Maryland-based company now says it will file for "Emergency Use Authorization" of its vaccine with the U.S. Food and Drug Administration (FDA).
Novavax Is a Long-Term Buy for the Continuing Pandemic
The Novavax vaccine does not require cold storage and could soon be available in international markets.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off the day with a look at the biggest pre-market stock movers for Thursday and it includes loads of medical stocks.
Is There Still Upside Potential for Novavax Stock?
Even though nearly 44% of Americans have been fully vaccinated, there is still plenty of profit potential left for NVAX stock.
What Will the Stock Market Do Today? 3 Big Stories to Watch.
So what will the stock market do today? All eyes are on an update to the Elon Musk Bitcoin saga and NVAX stock.
NVAX Stock: The Huge Vaccine News Helping Novavax Shoot Higher Today
Novavax reported positive results from its long-awaited Covid-19 vaccine trials. With G7 leaders promising more vaccines for poorer countries, NVAX could be a beneficiary.
There’s Good Reason to Believe Novavax Will Rise Soon
NVAX stock will release trial data soon and has multiple ways to win making it worth a look right now.
Despite Setbacks, the Future Remains Bright for Novavax Stock
Novavax has seen its highs and lows, but its best days appear ahead of it. And for NVAX stock investors, the opportunity looks massive today!
With a Stumbling Track Record, All Signs Say Stay Away from Novavax
Overseas Covid-19 vaccine deals could save the day, but it's hard to imagine the dwindling prospects of NVAX stock turning on a dime.
Once-Bright Light Novavax Stares Into a Dimming Future as Vaccine Also-Ran
Once a very promising play on the Covid-19 pandemic, Novavax has lost serious momentum, putting NVAX stock under question.
Are Children the Solution to Novavax’s Vaccine Problem?
Canada’s vaccination rate is about to pass the U.S. That does not bode well for Novavax and NVAX stock. Are children the company’s savior?
Novavax Window of Opportunity Is Closing Fast
NVAX stock is in danger of repeating prior failures. The window of opportunity is closing and it's a movie investors have seen before.
The Dip In Novavax Is The Perfect Buying Opportunity
With strong liquidity and a massive vaccine market, Novavax is perfectly positioned in the industry. NVAX stock is a good buy in the dip.
